Drugs / [F-18]MeFAMP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05676489 | Apr 2027 → Aug 2029 expected | glioma, metastatic malignant neoplasm in the brain | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [F-18]MeFAMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05676489 ↗ |
| Known as | (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid | “This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate,...” NCT05676489 ↗ |
| Known as | MeFAMP | “This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate,...” NCT05676489 ↗ |
| Modality | Diagnostic / imaging agent | “for positron emission tomography (PET) imaging of primary and metastatic brain tumors” NCT05676489 ↗ |